ZeClinics’ Post

🚀 𝐍𝐨𝐯𝐨𝐧𝐞𝐬𝐢𝐬: 𝐀 𝐅𝐫𝐞𝐬𝐡 𝐒𝐭𝐚𝐫𝐭 𝐢𝐧 𝐁𝐢𝐨𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬! United as one, we’re Novonesis, your global BioSolutions partner. With 10,000 bright minds and biology’s wonders, we’re set to lead a new era. Novonesis means ‘a new beginning’ and is derived from the Greek word ‘genesis’. Watch the video below to know more about why Novonesis is our new name. #Novonesis #NewBeginnings #Biosolutions

🚀 Exciting News from Natera Inc.! 🚀 We're thrilled to announce a 58% revenue surge in Q2 2024, thanks to high test volumes and ASP growth. We've also raised our guidance to $1.5B! 👉 Discover how we're leading the way in innovation and growth: [Read more](https://lnkd.in/dG-GywV3) 🎯 Join the conversation and let us know what you think in the comments! #NateraGrowth #InnovationInAction

Legacy Novozymes has delivered solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% in the financial year 2023. This marks the last financial reporting from legacy Novozymes. Learn more about the results in the press release below. #biosolutions #financialresults #novonesis legacy Novozymes announced its last full year announcement, delivering solid results with an organic sales growth of 5% and an EBIT margin of 25.4% before special items for the financial year 2023.

In 2024, CliniPsy invites you to embark on a unique inner journey. Become the pilot of your mind and set off on an adventure of self-discovery. At CliniPsy, every step is a leap towards your untapped potential. Our elite guidance is crafted to help you transcend your limits, unveil hidden strengths, and forge a radiant future. Make 2024 the year you reach new heights of personal growth, inner harmony, and excellence. CliniPsy is here to illuminate your path and support you at every stage of your transformation. Embrace change, welcome your evolution, and realize the full potential of your being with CliniPsy. #CliniPsy #innerjourney #personalgrowth #unlimitedpotential #eliteguidance #personaltransformation #selfdiscovery #innerharmony #excellenceinaction #personalsuccess

My good friend Thijs van Nuenen is - as to my concern - THE example of a scaleup entrepreneur. Someone who has led his company in 15 years from pioneer phase to the scaling up phase. I know he made a lot of sacrifices. But if someone has been showing resilience, it's Thijs. When he sold his company Medido last year, he celebrated by biking #100cols (it became 111) on his own. In the interview, Thijs explains how his role as entrepreneur changed in every growth phases and he found out in which phase he thrives best. You can also read when his company started to scale rapidly (by the book). I admire your work, the sacrifices and the ultimate reward Thijs. May many start- and scaleups follow your example! #scaleup #scalingup #growth #resilience

the goal of improving outcomes and controlling cost is available now not a vision for the future.

2024 is The Year for tackling Drug Mix by answering "What Drugs Do I Cover--And How?" Comparative Effectiveness Research is the answer used by all of our peer nations, which is one (of many) reasons they spend so much less on drugs than we do. If you want a refresher on what Comparative Effectiveness Research is and how it can help self insured employers and their advisors save on specialty, generic, non-specialty brands, and even high cost Cell/Gene therapies (with a better clinical benefit), I encourage you to check out this 3-minute refresher video courtesy of Chris Fisher and BenefitsAlly. https://lnkd.in/eJSxpfSJ

📽 In our latest video, Donal O'Shea, CEO of digital pathology company, Deciphex, and Brian Geraghty, Principal at Claret give a brief snapshot of Deciphex's innovative solutions that are revolutionising the industry. Hear from Donal as he also tells us:   🚀 Why venture debt was attractive as a non-dilutive funding option to support their growth journey 🤝 Why they chose Claret, and how we've supported the business as they continue to scale   "Since Claret has become involved with Deciphex, we've scaled our reach in international markets, we've grown our commercial organisations, we've grown in scale revenue. We've had the ability to do that through access to capital." Donal O'Shea, CEO of Deciphex.   Watch the video here! ⬇ #venturedebt #growth #digitalpathology #innovation

I've been approached by a few individuals who know me well, curious about how Prosidio , on its mission to redefine value in the Otolaryngology medical device market, navigates pricing decisions, especially in relation to shareholder influences. It's important to clarify that Prosidio isn't bound to private equity (PE) or venture capital (VC) partners. Our private ownership is integral to our mission, enabling us to revolutionize healthcare by providing accessible, high-quality medical devices. At Prosidio, our private ownership is more than a structural detail; it's a reflection of our mission to revolutionize healthcare with accessible, quality medical devices. While we're open to strategic partnerships that resonate with our values, our vision for the future remains firmly rooted in our commitment to affordability and excellence in patient care. As Prosidio continues to grow, our dedication to empowering healthcare professionals and patients around the world only intensifies. At this risk of sounding too Adam Neumann-ish, I do truly believe we're not just a company; but part of a movement towards a more accessible and sustainable future in healthcare. #valueinmedtech #ProsidioFocus #HealthcareMission #StrategicGrowth #healthcareVC #healthcare #medicaldevice #biotechVC #seedstage